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Abstract 
One of the claims sometimes advanced in favour of anti-doping is that allowing 
doping would lead to a uniform increase in performance in comparison to no 
doping. The idea is that if all athletes would use doping, this would just shift the 
playing field to a higher level without a change in ranking, but at a higher health 
cost. In this paper, we critique this contention. We first develop our theoretical 
framework, with reference to the so-called Red Queen effect. We then argue 
that, if doping were allowed, Red Queen effects would not be the rule. We also 
show that to some extent Red Queen effects would occur, but these would not 
necessarily be morally problematic. We end by developing an argument in 
favour of a more liberal approach of doping, since such would allow escaping 
from today's runaway effects of anti-doping efforts. 
Keywords: doping, anti-doping, sport, drugs, policy  
Wordcount: main text 6027, abstract 143 
 
Introduction 
Doping is vilified mainly because considered an unfair distortion of the playing field and a 
threat to the athlete’s health. Despite increasingly repressive anti-doping efforts under the 
guidance of the world anti-doping agency (WADA) doping remains prevalent in elite sport. 
According to WADA, based on adverse analytical findings (i.e. presence in urine or blood of 
forbidden substances), 1-2% of elite athletes use doping. Indirect evidence suggests that 
actual prevalence is much higher, ten times or even more, depending on the method of 
measurement and varying between sports and countries (Faiss et al., 2020; Hon et al., 2015; 
Petróczi et al., 2008; Ulrich et al., 2017). Anti-doping thus does not attain its goal of 
eradication of doping, despite far-reaching – and sometimes morally problematic – 
surveillance of athletes who have to report their 24hr whereabouts all-year round to allow 
unannounced urine collection by doping officers who visually identify the correct anatomical 
origin of the sample. Furthermore, up to 40% of athletes with a documented adverse 
analytical finding (the 1-2% of those tested) may not have intended to dope (Hon et al., 2015) 
and there are regular accounts of unlucky innocent athletes being sacrificed for the sake of 
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‘clean’ sport (Dimeo & Møller, 2018; Moston & Engelberg, 2016; Pluim, 2008). Anti-doping 
calls for additional resources for more stringent repression along an end-justifies-the-means 
prohibitionist discourse. Critical analysis of the arguments in favour of current anti-doping 
policies is therefore warranted since it may provide insight for developing alternative ways of 
dealing with doping in sport. 
 
The ethics of doping and anti-doping remain vividly debated (Brown, 1980; Dixon, 2008; 
Loland, 2009; Schneider & Butcher, 1993; Simon, 1984). The aim of the present paper is to 
single out one specific aspect and discuss it in more detail, thereby necessarily leaving aside 
many other important points. This aspect is that many stakeholders, such as athletes and 
spectators, but also pundits and scholars argue that allowing doping would eventually lead to 
a uniform increase in performance in comparison to no doping (Chwang, 2012; Martins, 
2018). The idea is that if all athletes would use doping, this would just shift the playing field 
to a higher level without a change in ranking. This would however come at a higher health 
cost, because of health risks of some forms of doping. The objective of this paper is to 
formulate our critique of this contention. We do this by first presenting our theoretical 
framework, with reference to the so-called Red Queen effect. We then show that Red Queen 
effects would not be the rule if the anti-doping rule would be relaxed. Moreover, to the extent, 
that some Red Queen effects could still be expected to occur, we think they would not 
necessarily be morally problematic. We then go on by showing that the absence of a Red 
Queen effect has normative consequences. We conclude by arguing in favour of a more 
liberal approach of doping, since such would allow escaping from today's runaway effects of 
anti-doping efforts. 
 
Red Queen effects 
In Lewis Carroll's ‘Through the Looking Glass, and What Alice Found There’, Alice and the 
Red Queen are running very fast but there is no change in their position relative to their 
environment. “Now, here, you see, it takes all the running you can do, to keep in the same 
place” [original emphasis], is the answer of the Red Queen to panting Alice’s observation of 
their apparent stasis, in spite of her intense physical effort (Carroll, 1871). In 1973, 
evolutionary biologist Leigh Van Valen used the Red Queen's race as a metaphor to make 
sense of his observation that the fossil records showed constant extinction rates for subtaxa of 
a large number of taxa (Valen, 1973). Van Valen coined the Red Queen effect for the co-
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evolutionary process in which the benefits of a new and costly adaptation of one species (S1) 
are in parallel offset by new and costly adaptations developed by that species' ecological 
predator, prey, host, parasite or competitor (S2), in response to the adaptations of S1. For 
example, when S1 got faster, S2 also became faster, leading to escalation and loss of 
ecological balance, pushing the two species towards extinction. In other words, both species 
would have been better off if they had not been caught up in such an evolutionary arms race. 
Evolutionary biology now uses the Red Queen effect to describe both inter- and intra-species 
runaway dynamics. As an example of the latter one can think of the increasing size of antlers 
in male deer, a costly male adaptation for competition for reproduction with females, that may 
have played a role in the extinction of the 'Irish Elk' whose palmate antlers had increased up 
to a span of 3.6 m (Worman & Kimbrell, 2008). 
 
 
Van Valen originally conceptualized the Red Queen effect as a macro-evolutionary trend to 
explain a general pattern in biological evolution. Soon, others used the Red Queen dynamics 
that Van Valen had sketched to explain escalation patterns on much shorter time scales. For 
example, it was argued that humans developed specialized cheater detection mechanisms in 
response to the development of sophisticated cheating mechanisms among their peers 
(Cosmides & Tooby, 2008). The Red Queen effect has also been used to account for similar 
dynamics outside the context of evolutionary biology. For instance, Gali (1994) has argued 
that conspicuous consumption is best explained as a Red Queen effect: people consume 
conspicuous goods in order to ‘keep up with the Joneses’. In the end, nobody improves their 
relative social rank, while everybody spends a lot of resources on things one does not need 
such as swimming pools, huge outdoor kitchens or SUVs. In The Economic Naturalist, Robert 
Frank suggests that the costs of such dynamics are not just financial, but can involve health 
costs as well (Frank, 2007). For example, some women may wear high heels to grab the 
attention of men, but when many women go along with this, at least part of the aesthetic 
advantage of wearing high heels is lost, while knee and ankle problems increase (Dawson et 
al., 2002). 
 
Although the term ‘Red Queen effect’ is not often used in debates on doping, the concept is 
(Danaher, 2012; Shermer, 2008). It is often argued and even more generally believed, for 
instance by many of the undergraduate students we have taught, that if doping were allowed, 
all athletes would consider doping as a requirement for their success in sport. Ubiquitous 
 
 
5 
doping and escalating doping use would then result in an invariant overall ranking, while 
morbidity and mortality would increase because of doping’s harmful side-effects. Chwang 
(Chwang, 2012) coined this a ‘positional treadmill’ effect and assumed its validity for his 
argument in favour of anti-doping. If one would allow doping, athletes would either start 
using doping or drop out. In that sense, all elite athletes wanting to compete would be obliged 
to use doping. Our main concern here is not with how engaging in doping can be seen as a 
prisoner’s dilemma. Rather, we are interested in two  special characteristics of the doping 
related prisoner’s dilemma that some anti-doping advocates highlight. The first characteristic 
is that everybody would be better off if no-one used doping (Breivik, 1992; Chwang, 2012). 
The second characteristic is that an escalated use can be expected as soon as doping use is 
allowed. Our argument rests on the debunking of several assumptions that underlie the anti-
doping advocates’ fear for dramatic Red Queen effects in sports if doping were allowed. 
In the first section, we will address the idea that it’s in everybody’s best interest to ban 
doping. We think there are good reasons to think that in general at least someone is better off 
if a substantial number of athletes or even every athlete would be doping. The ubiquity of 
interaction effects makes it unlikely that the athletic value ratio between two athletes will 
remain identical before and after the doping use. 
 
Interactions  
Our argument rests on the debunking of the assumption that allowing everyone to use doping 
would not change anything sport-relevant, because of a uniform upward shift of the playing 
field. One way of tackling this contention, is by arguing against the view that a uniform 
upward shift would not add anything to sports. For instance, one could argue that even if the 
ranking would remain unchanged if every athlete used doping, some aesthetic properties of 
the performance or the game would still be different (more or less aesthetically pleasing). This 
is not the angle we will take. The reason is that we think the empirical premise is just 
incorrect: if all current athletes would start doping, the future ranking in their sports would be 
affected. The assumption that the effect of a given doping technology is the same for all is 
flawed, as we show hereunder. We discuss what is known about the determinants of elite 
performance and interventions other than doping such as training on performance 
enhancement and then show that similar non-uniform patterns can be expected for doping.  
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The exercise-physiologist Per-Olof Åstrand allegedly once quipped that in order to become an 
Olympic athlete one should choose one’s parents wisely. Talent has a high heritability and a 
good potential for elite excellence can, on the condition of exposure to the right environment, 
be transformed into optimal performance, increasing one’s chances in elite competition 
(Baker & Wattie, 2018; Issurin, 2017; Moran & Pitsiladis, 2016; Sanchis-Gomar et al., 2016; 
Tucker & Collins, 2012). 
  
In the discussion of potential Red Queen effects in doping dynamics one should take into 
account the extent of inter-individual variation in this interaction between a given genetic 
endowment and a particular environment. Talent is to some extent heritable and hence 
unevenly distributed. Take aerobic capacity, a prime determinant of endurance performance. 
The greater the aerobic capacity, the greater the sustainable metabolic rate, the greater the 
energy available for muscle contraction and hence the greater the potential for endurance 
performance. In the Family Heritage Study, Claude Bouchard and colleagues studied the role 
of genotype in the cardiorespiratory and metabolic responses to aerobic exercise training 
(Bouchard et al., 1999). 742 healthy sedentary subjects with varying degrees of kinship, 17 to 
65 years old, were tested, exercise-trained in the laboratory under supervision with the same 
program for 20 weeks, and re-tested. The response to endurance training was found to be 
~50% heritable. While the average increase in aerobic capacity for an identical training 
stimulus was 19%, about 5% of the subjects had little or no change (<5%) while about 5% 
had an increase of 40%, and some even saw their aerobic capacity increase with more than 
50%. 29 genes predicted training response and 11 particular SNPs (single nucleotide 
polymorphism, a signature of genetic difference for a given gene between individuals of a 
species) captured 50% of the estimated variance attributable to genetic differences (Timmons 
et al., 2010). Not only the response to training, but also responses from interventions such as 
nutritional strategies vary importantly between individuals because of their genetic make-up 
(Baar, 2014; Joyner & Lundby, 2018; Pigeyre et al., 2016). 
  
Another illustration of different responses between athletes to a given intervention is altitude 
training, a common practice among endurance athletes. The underlying rationale is the 
following. The lack of oxygen from the thinning air at altitude induces low blood oxygen 
levels. These stimulate the production of erythropoietin (EPO), a hormone which drives the 
production of new red blood cells. These increase the oxygen-carrying capacity of the blood, 
a main determinant of aerobic capacity, and therefore endurance performance upon descent to 
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low altitude. However, there is important individual variation in the effects of an identical 
altitude exposure [responders and non-responders, (Millet et al., 2019; Siebenmann et al., 
2012; Sinex & Chapman, 2015)]. It is unknown what the underlying mechanisms are, but they 
are likely genetic. Instead of using altitude exposure to stimulate the organism’s EPO 
production, EPO can also be injected. When EPO appeared on the market, endurance athletes 
were quick to adopt its use, because it circumvented the complexity of altitude training. Again 
it was observed that the effects of EPO not only varied with dosage but also among 
individuals, and a debate on its effectiveness for elite performance is still ongoing (Clark et 
al., 2017; Hardeman et al., 2014; Heuberger et al., 2013). EPO is not the only substance with 
different effects between persons. In fact, it is true for many pharmaceuticals that some 
respond well to them and some do not respond, some will experience no side-effects and 
some will develop very strong side-effects.  
 
These interactions are so important that a separate field has emerged that studies how drugs 
affect individuals differently because of their particular genetic make-up. This field is called 
pharmacogenomics and the goods it will deliver encompass the possibility to individually 
tailor more effective and safer medication strategies. This burgeoning scientific field also 
holds promise for the development of personalized medicine approaches in order to adapt 
choice and dosage of pharmacology to the individual genotype and phenotype (Filipski et al., 
2016). There is all reason to expect that such variation in effects also applies to most doping 
substances, and even that performance-relevant three-way interactions between doping 
substances, training intensity and genes are not rare. In other words, it is naïve to assume that 
doping use by all elite athletes would not affect the ranking. In part because of the important 
interaction effects we underscored in this section, it is also naïve to think that allowing doping 
necessarily leads to an escalated use of doping. We will further develop this issue in the next 
section.  
 
Escalation 
The next assumption we address is that allowing doping would lead to a true arms race in 
which every athlete would dangerously escalate their use of substances so as to incur 
significant health risk. We present two arguments that question this assumption. We first 
make a distinction between escalations of amount and escalations of risk, and then question 
the use of game theory to predict that what has not yet come, a runaway catastrophe.  
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Some anti-doping proponents argue or assume that a liberal doping policy would lead to 
runaway effects of dosage since more is believed to be better. For any pharmacological 
substance there are three questions that need to be answered: What is the magnitude of effects 
(beneficial or adverse) from a given dose? How quickly will any given effects occur? And 
how long will these effects last? (Wright et al., 2011) For any substance used for performance 
enhancement the answers to these questions vary according to the specific pharmacology 
(kinetics and dynamics) of the substance and the physiology of the user. Importantly, the 
effects of a substance do not scale linearly with its dosage (Wright et al., 2011). To enhance 
one’s performance, an optimal dose of a drug needs to be taken. Importantly, the optimal dose 
is not necessarily a high dose. In some cases, the dose can even be relatively low. Because the 
poison is in the dose, this also entails that coincidence between the best performance 
enhancement effect and lethal risk is far from necessary and quite often simply unlikely. For 
example, in precision sports such as shooting, archery and biathlon tremor can be controlled 
and shooting performance improved with a beta-blocker dosage that remains below lethal 
because of the ergolytic effects of increasing dose (Kruse et al., 1986). Caffeine improves 
exercise performance in a broad range of exercise tasks at dosages much below lethal ones 
(Grgic et al., 2019). Sure, excessive intake of about anything is dangerous and even water can 
be deadly when consumed in excess and actually is, when slow marathon runners take the 
sports drink industry’s marketing slogan ’drink before you are thirsty’ too literally and 
subsequently develop hyponatraemia leading to sometimes lethal brain oedema (Hew-Butler 
et al., 2017). It thus follows that the argument of escalation of amount simply because more is 
better does not hold.  
 
The second part of the escalation argument states that athletes are prone to taking more than a 
reasonable amount of a doping substance. They therefore risk significant health harm and 
should be protected from themselves. To bolster this argument the anti-doping literature 
frequently cites the so-called Goldman dilemma. It states that a majority of athletes is willing 
to ingest a magic pill if it could make them an Olympic champion, even if it would kill them 
in 5 years (Goldman & Klatz, 1992). Christiansen and Møller (Christiansen & Møller, 2007) 
tried to find the original research by Mirkin, cited in Goldman’s book, and concluded that the 
study was probably never formally conducted. Since then, several published studies have 
rejected Goldman’s claims (Connor & Mazanov, 2009; Connor et al., 2013). There is 
therefore no reason to believe the dramatic postulate of Mirkin and Goldman. There is also no 
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good epidemiological evidence for excessive morbidity and mortality before the advent of 
modern anti-doping, when doping was supposedly frequent, for example in professional 
cycling. Individual cases such as that of the death of Knud Enemark Jensen in the Rome 
Olympics of 1960 and that of Tom Simpson during the 1967 Tour de France are repeatedly 
cited as proof, even though the role of doping in their deaths remains unclear (López, 2013; 
Møller, 2005). Overall, there is no indication of excess morbidity or mortality among athletes 
in the heyday of doping with an exception for state-imposed doping of - especially female - 
athletes with anabolic steroids in East-Germany (Dimeo & Hunt, 2012; Franke & Berendonk, 
1997). In contrast, there is good evidence that longevity is better among former Olympians 
and Tour de France cyclists (Teramoto and Bungum 2010; Marijon et al. 2013; Clarke et al. 
2015). The anti-doping discourse frequently predicts catastrophe if doping were allowed. 
According to historian Lopez such anti-doping discourse is an example of fear mongering at 
the service of a social control and surveillance agenda. He argues that the evidence base for 
doping’s excessive dangerousness is often shallow (López, 2013, 2016). 
 
Of course, we do not want to deny that many pharmacological substances come with 
potentially very dangerous side effects. For many substances, if taken in excess or taken in 
inappropriate ways, the health risks are real. For example, excessive use of over-the-counter 
anti-inflammatory drugs by athletes (and by the general public, for that matter) can have very 
harmful side-effects (Warden, 2015), and non-medically supervised use of anabolic steroids, 
for example by body-builders, can lead to major health problems (Karila et al., 2003; 
McVeigh & Begley, 2016). However, when considering doping substances the risks are often 
exaggerated especially in comparison to other risks people partake in on a daily basis. 
 
Other arguments for the risk of escalation in doping use build upon game theoretical 
approaches and insights (Breivik, 1992; Shermer, 2008; Strulik, 2012). Van Valen already 
thought of the Red Queen effect in terms of game theory, with each species taking part in a 
zero-sum game against the other species in which no species can ever win, and where new 
adversaries ‘grinningly replace the losers’ (Valen, 1973). Applied to doping the simplest 
game theory scenario is as follows. If athlete A refrains from doping, then athlete B will gain 
an advantage by doping. If athlete A uses doping, it is also in the interest of athlete B to use 
doping, to try and keep up. It follows that since B does not know for sure what athlete A is 
doing, it is a better idea to use doping than not to. The same reasoning accounts for athlete A 
and the end-result tends therefore towards pervasive doping. Here, doping use is the strategy 
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of a rational athlete confronted with a simple prisoner’s dilemma. The Red Queen effect thus 
occurs where defecting is not just the rational choice, but where ever more defecting is 
rational and escalation towards ever more doping would thus be expected. This shift, towards 
doing what the other is suspected to be doing to improve performance, is not uncommon; the 
same mechanism is at work for other means used to gain an edge over the opponent, such as 
better exploiting the possibilities of training, nutrition, material, etc. 
 
Chwang for example, also uses a game theoretical approach in his plea in favour of anti-
doping. He starts from the premise that doping is harmful to dopers (Chwang, 2012). 
Reasoning that allowing doping would shift the playing field uniformly up if all athletes 
engaged in doping (prisoner’s dilemma) he then posits that athletes would prefer not to dope 
because of its harm and lack of a competitive advantage (Red Queen effect). An impartiality 
premise then states that one should not allow some athletes to dope but not others. A 
beneficence premise, that we should give athletes what they want (i.e. a preference for no 
doping), then leads Chwang to conclude that one should therefore ban doping (Chwang, 
2012).  
 
We already demonstrated that the premise of a uniform shift of the playing field is flawed and 
that Red Queen effects would not be the rule when doping were allowed. Equally important is 
that we have serious doubts that the game theoretical models adequately predict the behaviour 
of athletes. Game theoretical models attempting to explain or predict doping behaviour cannot 
be tested against empirical data because of the covert nature of the behaviour and for fear of 
catastrophe if doping were allowed. However, the literature on the psychology and sociology 
of doping suggests a rich pattern of factors influencing doping behaviour where rational 
choice is not the rule (Elbe & Barkoukis, 2017; Ring et al., 2017; Smith, 2016). More 
generally, human decision-making exhibits a suite of biases when making economic 
decisions. For example, it is not uncommon to take (unreasonable) long term risk for short 
term return (Jolls et al., 1998), a bias that has probably evolved in our lineage, like many 
similar biases (Santos & Rosati, 2015). Likewise, although the most rational strategy in a ‘war 
of attrition’-like auction is to bid more than the value of the product that one is bidding for, 
people are never willing to pay a million dollars for a dollar in a so-called dollar auction, even 
that is what they would end up doing if they made all rational choices (Teger, 2017). Given 
the complex determinants of human behaviour, it is therefore difficult to predict what would 
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happen under a liberal doping policy, and game theory will often generate the wrong 
predictions. Or, as game theorist and economist Ariel Rubinstein put it:  
There are those who believe that the goal of game theory is ultimately to 
provide a good prediction of behaviour in strategic situations […]. I am not 
sure on what this vision is based. Most situations can be analysed in a 
number of ways, which usually yield contradictory ‘predictions’. 
(Rubinstein, 2007) 
 
We acknowledge that due to the extreme stakes in elite sports,  some athletes would decide to 
use substances in excess of reasonable health risks if doping were allowed, similarly to the 
important other health risks related to their sport that athletes are willing to take. But 
optimising doping use, i.e. exploiting its performance enhancing effects while balancing this 
with the potential health risks, is not the same as escalation of amount of doping use. Even if 
game theory would suggest the potential for escalation of health risk from escalation of 
doping use, this is not necessarily the case, as illustrated by what was the situation before the 
advent of modern anti-doping. We therefore conclude that pervasive escalation of dosage 
among athletes would not be the rule, although we do acknowledge that some athletes and 
support personnel might incorrectly believe that more is always better and would be willing to 
take excessive risk.  
 
So far our reasoning has concerned doping substances considered to be objectively dangerous. 
Athletes and the public at large mostly assume that substances on WADA's 'Prohibited List' 
are both performance enhancing and dangerous. But WADA does not communicate the 
reasons for adding a particular substance to its List. As is well-known, three criteria are used 
of which at least two have to be met: 1) enhancing, or having the potential to enhance, 
performance; 2) posing an actual or potential health risk; and 3) being contrary to the ‘spirit of 
sport’. Apart from its catch-all approach due to the inclusion of ‘the spirit of sport’, it is clear 
that for many substances on the List there is no good evidence that they enhance performance 
or cause harm (Heuberger & Cohen, 2019). The List contains substances for which 
dangerousness can be considered acceptable or even absent, even though the adage ‘the dose 
makes the poison’ remains correct (even water can be deadly when taken in excess). The ban 
on doping and WADA’s decision process on the List maintain general ignorance, with 
unintended but potentially harmful effects (Fincoeur et al., 2013; Milot, 2014). For instance, 
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athletes may take illicit substances that actually do not enhance performance but might cause 
harm, while licit substances such as NSAIDS (e.g. paracetamol, ibobrufen) are frequently 
used by athletes, for which the balance between the therapeutic effect, performance 
enhancement and harm from side-effects are not clear (Warden, 2015). 
  
In the context of escalation, it is important to note that the List includes non-harmful 
substances besides genuinely harmful substances. Take meldonium, for which in healthy 
individuals there is not only no evidence for improvement of performance but also no 
evidence of a relevant health risk (Negro et al., 2018). Or take aromatase inhibitors such as 
exemestane, which lead to a modest increase in testosterone with little side-effects 
(Lintermans et al., 2011). This entails that even if the use of these substances escalates, the 
negative health effects of the escalation may sometimes be less than the negative health 
effects of escalating training and dieting practices (Brenner, 2007; Carlsohn et al., 2011).   
 
A better competition through doping? 
In the previous sections, we argued that Red Queen effects would not be the rule as soon as 
doping would be allowed in sports. We presented what we believe is  good evidence for the 
view that the effects of interventions to improve performance, be it training, nutrition, or 
(il)licit substance use, vary importantly between individuals and that a non-uniform stimulus-
response is the rule. This evidence invalidates the claim that pervasive doping would just shift 
the performance level uniformly up, leading to a zero-sum result. Obviously, this does not 
entail that the anti-doping stance needs to be given up. It just entails that one specific 
argument in the debate against allowing doping is shown to be flawed.  
Some readers may find our critique of this particular argument compelling, while at the same 
time thinking that the empirical components of our argument can just as well be used in an 
argument against the relaxation of anti-doping. In a nutshell, such an anti-doping argument 
would go as follows: the doping ban is legitimate because allowing doping would result in 
winners who would have no chance if they wouldn’t take doping. Doping use alters 
something essential about sports, and reduces the impact of exercise, skill and talent on the 
ranking. After all, the varying responses to pharmacology, can be expected to add to the 
variation in performance between individuals, thus leading to new and allegedly undeserving 
winners and new allegedly undeserving losers. According to philosophers such as Loland, this 
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justifies a doping ban, since doping enhances performance in an artificial (‘unnatural’) way 
and also impacts the ranking (Lenk, 2013; Loland, 2018). 
To a large extent, this anti-doping argument hinges on what counts as fairness in an athletic 
context, a contentious and much debated topic within the ethics of sports. Instead of 
reiterating all the existing arguments in this debate, we want to emphasize here that the 
interaction effects we discussed can also be used to boost fairness arguments in favour of a 
relaxation of current doping policies. This suggests that the link between varying athletic 
responses to pharmacological products and the fairness of athletic competitions is less 
straightforward than some may think, although it is obviously insufficient to demonstrate that 
the use of doping is unproblematic from a fairness perspective. But how can these arguments 
for a more liberal doping policy be boosted by the interaction effects we discussed? 
 
First, there is the issue that most gene-environment interactions are not seen as a threat to 
fairness by those who consider interactions that involve substance use to lead to unfair 
outcomes. Indeed, today’s elite  playing field can be understood as bringing together 
individuals with a largely similar phenotype (i.e. sharing a similar level of performance), 
based on an unusual but given genetic background, brought to optimal expression in a certain 
environment (Issurin 2017). As long as the elite athletes do not use doping, their triumphs are 
not seen as unfair, even though they have little merit in much of their upbringing (their diet as 
a child, the climatological circumstances in which they developed, the affluence of their 
parents and home country, …) or in their genes. Elite athletes are engaged in a continuous 
tweaking of their environmental exposure to obtain optimal responses (by means of training, 
nutrition, supplements, psychology, etc.) and performance has become a highly technological 
endeavour with many people involved in athlete preparation (coach, trainer, psychologist, 
nutritionist, physiologist, doctor, etc.). Adding doping as an additional means for tweaking 
could be seen as further adding variance to performance, an additional means that is not 
intrinsically less ethical than the often not much less ‘artificial’ means that are currently 
allowed. 
 
Secondly, zero-tolerance does not lead to zero use, and we are highly sceptical that the ‘war 
on doping′ will ever be absolutely successful. Hence, even though the ‘war on doping′ is in 
full swing, as illustrated in the Introduction, doping is still being used by some winners who 
would never be a winner if all competitors abstained from doping. Moreover, one could even 
argue that there is some moral value in the fact that there are people who thanks to doping can 
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be given the chance to compete with others. It would allow those with lesser base capital in 
one currency to exploit their larger base capital in (a hitherto forbidden) currency (Bonte, 
2013). Because of the complexity of getting the tuning right, one could value this difficult 
endeavour as much as the hardship of training and optimal athlete support, giving it greater 
(aesthetical and/or ethical) value than the free but undeserved baseline talent. Seen in this 
way, doping could thus be thought to change something sport relevant in a way that is not 
necessarily negative.  
 
What about health?  
Fairness is one cornerstone of anti-doping arguments and policies, but health is arguably even 
more important. Hence, one obvious objection to our view is that relaxation of the doping ban 
will have dramatic health effects. Part of this issue was already addressed in the section on 
escalation. Still, even without an escalation of doping use, some may expect an increase of the 
health risk after the relaxation of the doping ban. We agree that this is a potential problem, but 
think that the risk depends to a large extent on how this relaxation is implemented. We discuss 
in this section how these relaxation measures and their effects on health are related to Red 
Queen effects.   
 
Current anti-doping is prohibitionist and aimed at abstinence from a ‘zero-tolerance’ 
standpoint. What would be the effects of a policy change allowing doping within a health 
surveillance perspective? Without detailing the undoubtedly complex operationalisation, two 
different scenarios can be envisaged. First, a really open scenario can be envisioned, with no 
cut-off for any given intervention, leaving it to the athlete and their support team to decide on 
how to exploit any performance enhancement means. A closed scenario is also possible, with 
a cap to some (patho-)physiological effect, if beyond such a cut-off the health risk would be 
deemed excessive by some regulating instance. An example of an open scenario would be to 
take substances off the List such as meldonium (Negro et al., 2018). Athletes would be 
allowed to use meldonium at their discretion, but would be monitored to study the effects 
(good and bad). An example of a closed scenario would be to allow the use of EPO, but up to 
a maximum level of red-cell content of blood (i.e. haematocrit) of 50%, a measure that was 
already introduced by the UCI (International Cycling Union) in 1997 on the basis of the idea 
that beyond 50% the health risk would increase irresponsibly (Neumayr et al., 2002). 
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In the open model the varying frequencies and intensities of interventions chosen by the 
athletes, combined with the varying effects of such interventions between them, would 
exclude a Red Queen effect but instead add variance to the playing field. In the closed model, 
some Red Queen effects might be expected to the extent that e.g. an identical haematocrit (red 
blood cell content) would put all athletes on par for that specific variable, even though it can 
still be expected that the interaction with various other varying parameters would not 
eliminate overall variance of performance. Indeed, it is not obvious that for a given fixed level 
of some physiological parameter, e.g. haematocrit, or plasma growth hormone concentration, 
the overall physiological effect on performance would be identical between athletes. As we 
have explained earlier, the contrary is much more likely, since such parameters always 
interact with many others in a complicated dynamic.  
 
Because of anti-doping measures, it has become very difficult to discover the performance 
and health effects of substances on the List, which also entails limitations for our approach. 
We have discussed the potential for doping runaway effects taking into account the 
(incomplete) empirical data available, making assumptions as realistic as possible. But the 
state of ignorance on the effects of doping, good and bad, that modern anti-doping has 
created, necessarily renders most arguments about the health risks of doping speculative. Still, 
we believe that the central claims of our paper rest on solid foundations. We contend that the 
argument that allowing doping would lead to a uniform increase in performance does not hold 
and should not be used anymore in arguments in favour of anti-doping policy. In sports, some 
limited Red Queen effects occur, but only up to the level that changes in behaviour of one’s 
opponent (training, diet, supplements, doping) may lead to some level of adoption of such 
behaviour in the other athlete. But because of the varying effects to identical stimuli between 
athletes, the outcome will not level out, but instead will introduce further variance of 
performance. If the anti-doping rule would be relaxed, it would then be expected that the 
playing field would remain at least as dynamic as it is today, opening the way towards valuing 
the exploitation of baseline talent by all means, including doping. 
 
For now anti-doping is asking for the contrary, more means in order to eradicate doping. The 
CEO of the world association of Olympians suggested to implant a chip into all athletes 
world-wide (Kelner, 2017). Extension of nootropic drug testing to coaches was proposed 
(Rodenberg & Holden, 2017)This dynamic is akin to the advent of the general ‘war on drugs′, 
which was eventually proven to be a costly failure (Room & Reuter, 2012). We find that 
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modern anti-doping policy itself shows Red Queen like runaway dynamics in an 'end-
justifies-the means' fashion. This policy is engaged in a spiralling ‘war on doping′ that does 
not and presumably cannot attain its goal, eradication of doping in elite and amateur sport. 
Ever more sophisticated means to detect doping use will lead to ever more sophisticated 
means to use doping. Ironically, such increasingly drastic measures are (sometimes) 
motivated by a fear that a relaxation of the anti-doping regulations would result in dramatic 
Red Queen effects. Of course, we do not deny that the current policy has had its partial 
successes. Yet, we do believe that less costly policies could be more successful, and that a 
successful policy should definitely not start from the wrong-headed assumption that allowing 
doping wouldn’t alter the ranking, and would lead to an uncontrollable escalation of the use of 
unhealthy substances.  
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